Idioma:

Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy

Watanabe, Maki ; Nishikawaji, Yuya ; Kawakami, Hirotaka ; Kosai, Ken-Ichiro

Viruses, 2021-12, Vol.13 (12), p.2502 [Periódico revisado por pares]

Switzerland: MDPI AG

Texto completo disponível

Citações Citado por

Enviar para

Título:
Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy
Autor: Watanabe, Maki ; Nishikawaji, Yuya ; Kawakami, Hirotaka ; Kosai, Ken-Ichiro
Assuntos: Adenoviridae - genetics ; Adenoviridae - physiology ; Adenoviridae Infections - virology ; Adenovirus ; Adenoviruses ; Animals ; Apoptosis ; Biology ; Cancer ; cancer immunotherapy ; Cancer therapies ; Cancer vaccines ; Cell cycle ; Cell Line, Tumor ; Clinical trials ; conditionally replicating adenovirus ; COVID-19 - prevention & control ; COVID-19 Vaccines ; cytokine ; Gene Expression ; Gene therapy ; Genetic Therapy ; Genetic Vectors ; Genomes ; Humans ; Immunotherapy ; Infections ; Insertion ; m-CRA ; Oncolysis ; Oncolytic Viruses - genetics ; Pluripotency ; Pluripotent Stem Cells ; Promoter Regions, Genetic ; Proteins ; Regenerative medicine ; Replication ; Review ; SARS-CoV-2 ; Stem cells ; Survivin ; Therapeutic applications ; Tumors ; Vaccines ; Vectors (Biology) ; Viral infections ; Virus Replication ; Viruses
É parte de: Viruses, 2021-12, Vol.13 (12), p.2502
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Equally contributed.
Descrição: Gene therapy is currently in the public spotlight. Several gene therapy products, including oncolytic virus (OV), which predominantly replicates in and kills cancer cells, and COVID-19 vaccines have recently been commercialized. Recombinant adenoviruses, including replication-defective adenoviral vector and conditionally replicating adenovirus (CRA; oncolytic adenovirus), have been extensively studied and used in clinical trials for cancer and vaccines. Here, we review the biology of wild-type adenoviruses, the methodological principle for constructing recombinant adenoviruses, therapeutic applications of recombinant adenoviruses, and new technologies in pluripotent stem cell (PSC)-based regenerative medicine. Moreover, this article describes the technology platform for efficient construction of diverse "CRAs that can specifically target tumors with multiple factors" (m-CRAs). This technology allows for modification of four parts in the adenoviral E1 region and the subsequent insertion of a therapeutic gene and promoter to enhance cancer-specific viral replication (i.e., safety) as well as therapeutic effects. The screening study using the m-CRA technology successfully identified survivin-responsive m-CRA (Surv.m-CRA) as among the best m-CRAs, and clinical trials of Surv.m-CRA are underway for patients with cancer. This article also describes new recombinant adenovirus-based technologies for solving issues in PSC-based regenerative medicine.
Editor: Switzerland: MDPI AG
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy

Watanabe, Maki ; Nishikawaji, Yuya ; Kawakami, Hirotaka ; Kosai, Ken-Ichiro

Switzerland: MDPI AG

Buscando em bases de dados remotas. Favor aguardar.